ArticleJournal of the National Cancer Institute2020
Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort.
Article in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Late effects among colorectal cancer survivors ≥5 years after diagnosis-a systematic scoping review.JNCI cancer spectrum · 2026Article
- Plasma Multiomics Links Early-Life Adversity to Disease and Cardiometabolic Health: A Population-Based Cohort Study.Journal of the American Heart Association · 2026Article
- Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review.Journal of endocrinological investigation · 2026Review
- New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study.Diabetes, obesity & metabolism · 2026Article
- Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming.NPJ biofilms and microbiomes · 2026Review
- Risk of Type II Diabetes Mellitus Among B-Cell Non-Hodgkin's Lymphoma Survivors.Cancer medicine · 2026Article
- Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs.Korean journal of radiology · 2026Review
- The Risk of Type 2 Diabetes among Older Asian, Native Hawaiian, and Pacific Islander Colorectal Cancer Survivors: A Population-Based Study Using the SEER-Medicare Database.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Language-model-based patient embedding using electronic health records facilitates phenotyping, disease forecasting, and progression analysis.Research square · 2024Article
- New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.Scientific reports · 2022Article
- Review
- Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.International journal of molecular sciences · 2021Review
- Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies.ESMO open · 2021Article
- Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundThere are an estimated 1.4 million colorectal cancer (CRC) survivors in the United States. Research on endocrine and metabolic diseases over the long term in CRC survivors is limited. Obesity is a risk factor for CRC; thus it is of interest to investigate diseases that may share this risk factor, such as diabetes, for long-term health outcomes among CRC survivors.
methodsA total of 7114 CRC patients were identified from the Utah Population Database and matched to a general population cohort of 25 979 individuals on birth year, sex, and birth state. Disease diagnoses (assessed over three time periods of 1-5 years, 5-10 years, and >10 years) were identified using electronic medical records and statewide ambulatory and inpatient discharge data. Cox proportional hazard models were used to estimate the risk of endocrine and metabolic disease.
resultsAcross all three time periods, risks for endocrine and metabolic diseases were statistically significantly greater for CRC survivors compared with the general population cohort. At 1-5 years postdiagnosis, CRC survivors' risk for diabetes mellitus with complications was statistically significantly elevated (hazard ratio [HR] = 1.36, 99% confidence interval [CI] = 1.09 to 1.70). CRC survivors also experienced a 40% increased risk of obesity at 1-5 years postcancer diagnosis (HR= 1.40, 99% CI= 1.66 to 2.18) and a 50% increased risk at 5-10 years postdiagnosis (HR = 1.50, 99% CI= 1.16 to 1.95).
conclusionsEndocrine and metabolic diseases were statistically significantly higher in CRC survivors throughout the follow-up periods of 1-5 years, 5-10 years, and more than 10 years postdiagnosis. As the number of CRC survivors increases, understanding the long-term trajectory is critical for improved survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.